ClinicalTrials.gg
Active, not recruitingNCT07465029Updated Oct 1, 2026

A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

An observational study in Lower-risk Myelodysplastic Syndromes (TD LR-MDS), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Observational

How we know

Updated Oct 1, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 5 of them phase 3. Myelodysplastic Syndromes · Bristol-Myers Squibb.

Planned enrollment
3rd of 28
1,300 · median 200
Started
2026
with 2 others
Observational
28 of 75
3 open now
Registered
74th of 75
by date

Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 3rd largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, and was the 74th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

4 of the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain

03

Conditions studied

  • Lower-risk Myelodysplastic Syndromes (TD LR-MDS)

Keywords

  • Transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult participants diagnosed with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) identified in Spain using the BIG-PAC® database

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the time of lower-risk myelodysplastic syndromes (LR-MDS) diagnosis.
  • Documented diagnosis of LR-MDS identified through International Classification of Diseases (ICD) 9 codes recorded in medical history. In addition, recorded diagnosis of MDS with an explicitly documented International Prognostic Scoring System (IPSS) category of low or intermediate-1 and/or revised IPSS category of very low or low at or around the index date.
  • Evidence of transfusion dependence, defined as receiving ≥2 red blood cell (RBC) units within an 8-week interval, occurring within the selection window (January 1, 2021, to May 31, 2025, or the latest date ensuring detectable follow-up).
  • Active participants in BIG-PAC®, defined as ≥1 claim of any kind within 12 months prior to or on the index date (baseline period).
  • A minimum of 6 months of follow-up data available after the index date, unless the patient dies earlier

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of high-risk MDS (HR-MDS) or another hematologic (e.g., acute myeloid leukemia) before the index date.
  • Documented transformation to acute myeloid leukemia (AML) or HR-MDS occurring before initiation of treatment.
  • Participation in interventional clinical trials during the period of first-line treatment.
  • Presence of anemia secondary to non-MDS-related causes, such as nutritional deficiencies, advanced chronic kidney disease, or active bleeding, when such conditions preclude accurate attribution of transfusion dependence to MDS.
  • Lack of sufficient clinical history, defined as \<12 months of observable data before the index date.
  • Have missing key variables, e.g., age or sex.
  • Incomplete or inconsistent clinical information that prevents reliable evaluation of key study variables, including transfusion dependence status, treatment patterns, or outcomes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Overall cohort of participants with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)

    Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion

  • Cohort 2

    Participants that initiated first-line treatment with erythropoiesis-stimulating agents (ESAs)

    Drug: Erythropoiesis-stimulating agents (ESAs)

  • Cohort 3

    Participants that initiated first-line treatment with luspatercept

    Biological: Luspatercept

  • Cohort 4

    Participants that initiated first-line treatment with hypomethylating agents (HMAs)

    Drug: Hypomethylating agents (HMAs)

  • Cohort 5

    Participants that initiated first-line treatment with lenalidomide

    Drug: Lenalidomide

  • Cohort 6

    Participants that receive conservative management (red blood cell transfusions without disease modifying therapy)

    Biological: Reb blood cell transfusion

  • Cohort 7

    Participants with low red-blood cell (RBC) transfusion dependance (\<4 RBC per 8 weeks)

    Biological: Reb blood cell transfusion

  • Cohort 8

    Participants with moderate red-blood cell (RBC) transfusion dependance (4-5 RBC per 8 weeks)

    Biological: Reb blood cell transfusion

  • Cohort 9

    Participants with high red-blood cell (RBC) transfusion dependance (≥6 RBC per 8 weeks)

    Biological: Reb blood cell transfusion

  • Cohort 10

    Participants aged \<75 years

    Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion

  • Cohort 11

    Participants aged ≥75 years

    Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion

Interventions

  • DrugErythropoiesis-stimulating agents (ESAs)

    According to the product label

  • BiologicalLuspatercept

    According to the product label

  • According to the product label

  • DrugHypomethylating agents (HMAs)

    According to the product label

  • BiologicalReb blood cell transfusion

    According to the product label

06

What researchers measure

Primary outcomes

  1. Incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)

    Time frame: Up to 5-years

  2. Prevalence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)

    Time frame: Up to 5-years

Secondary outcomes

  1. Proportion of participants receiving each first-line treatment category

    Treatment categories include: * Erythropoiesis-stimulating agents (ESA) * Luspateracept * Hypomethylating agents (HMAs) * Lenalidomide * Conservative management (red-blood cell (RBC) transfusions without disease modifying therapy)

    Time frame: Up to 5-years

  2. Proportion of participants by treatment category at each line of therapy

    Treatment category received at each line of therapy (first line, second line, third line and beyond), categorized as erythropoiesis-stimulating agents (ESA), luspatercept, hypomethylating agents (HMA), lenalidomide, or conservative management (red blood cell transfusions without disease-modifying therapy). Treatment sequences will be derived from retrospective medical chart abstraction of documented treatment start and stop dates.

    Time frame: Up to 5-years

  3. Treatment duration (time from initiation to discontinuation) of first-line treatment

    Time frame: Up to 5-years

  4. Defined as number of RBC units received per participant per 8-weeks

    Time frame: Up to 5-years

  5. Number and Rate of Healthcare Resource Utilization Events

    Healthcare resource utilization events, including primary care visits, specialist visits, outpatient visits all-cause hospitalizations, transfusion-related hospitalizations, general laboratory tests, number of prescriptions related to transfusion-dependent lower-risk myelodysplastic syndromes, red blood cell transfusions, use of concomitant medicines related to other comorbidities as documented in participant medical records.

    Time frame: Up to 5-years

  6. Number of participants that achieve hematologic improvement-erythroid (HI-E)

    Time frame: Up to 5-years

  7. Number of participants that achieve red-blood cell (RBC) transfusion independence (TI)

    Time frame: Up to 5-years

  8. Number of participants that experience a change in transfusion burden (change in number of red-blood cell units received per 8-weeks)

    Time frame: Up to 5-years

  9. Number of participants that progress to higher-risk myelodysplastic syndromes (MDS)

    Time frame: Up to 5-years

  10. Number of participants that progress to acute myeloid leukemia (AML)

    Time frame: Up to 5-years

  11. Number of participants that do not respond to first-line treatment

    Time frame: Up to 5-years

  12. Number of participants that experience loss of response/secondary failure after an initial hematologic response

    Time frame: Up to 5-years

  13. Cause of death

    Time frame: Up to 5-years

  14. Serious adverse events (SAEs)

    Time frame: Up to 5-years

  15. Number of serious cardiovascular events requiring emergency room visit or hospitalization

    Cardiovascular events include: will include acute myocardial infarction or acute coronary syndrome, heart failure decompensation, clinically significant arrhythmias (including atrial fibrillation/flutter and ventricular arrhythmia), stroke or transient ischemic attack, and venous thromboembolism.

    Time frame: Up to 5-years

  16. Participant age

    Time frame: Baseline

  17. Participant sex

    Time frame: Baseline

  18. Year of first-line treatment initiation

    Time frame: Baseline

  19. Participant Body mass index (BMI)

    Time frame: Baseline

  20. Participant Charlson Comorbidity Index (CCI) score

    Time frame: Baseline

  21. Participant Charlson Comorbidity Index (CCI) individual comorbidities

    Time frame: Baseline

  22. Number of comorbidities

    Time frame: Baseline

  23. Smoking status

    Time frame: Baseline

07

Study locations

1 site
  • Local Institution - 0001
    Madrid, 28001, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2026 to primary completion in Apr 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2026 → Apr 2026 and completion May 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 11, 2026
StartActual
Feb 2, 2026
Primary completionActual
Apr 23, 2026was Mar 2026
CompletionEst.
Nov 27, 2026was May 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 31, 2026→Apr 23, 2026 (actual)
Oct 1, 2026
Study completion
May 31, 2026→Nov 27, 2026
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Mar 31, 2026→Apr 23, 2026 (now actual)
    Study completion May 31, 2026→Nov 27, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07465029
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Feb 2, 2026
Primary completion
Apr 23, 2026
Completion
Nov 27, 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion